---
title: Improve standing reach and strength
nct_id: NCT07382674
phase: NA
status: RECRUITING
sponsor: Emory University
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07382674"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07382674"
last_fetched: "2026-05-26T14:01:20.453Z"
source: "Parkinson's Pathways (curated)"
---
# Improve standing reach and strength

**Goal (in five words):** Improve standing reach and strength

**Official Title:** Zesty Exercise System for Therapeutic Engagement

**Trial ID:** [NCT07382674](https://clinicaltrials.gov/study/NCT07382674)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Emory University
- **Target Enrollment:** 46 participants
- **Start Date:** 2026-03-16
- **Completion Date:** 2028-02
- **Conditions:** Parkinson Disease
- **Interventions:** ZEST-E Robot-Assisted Exercise Program
- **Intervention Types:** DEVICE

## Summary For Families

The goal is to help people with mild to moderate Parkinson’s improve movement, balance, and everyday function by using targeted, repetitive exercise that promotes motor learning and strengthens neural pathways. The ZEST-E program is a robot-assisted exercise system that supports or guides limb movements, adjusts challenge levels, and gives real-time feedback so sessions are safer, more intensive, and more likely to retrain movement patterns, and it is meant to be used alongside a person’s regular medications rather than replace them. The trial is enrolling adults 40 and older with mild to moderate PD (roughly Hoehn and Yahr stages 1 to 3) who can complete study procedures and have a MoCA of 17 or higher, while excluding people with recent stroke, uncontrolled cardiac or other serious medical issues, certain psychiatric or substance use disorders, or medications that impair cognition.

## Eligibility

- **Minimum age:** 40 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

-Older adults with mild to moderate PD.

Exclusion Criteria:

* Acute medical illness requiring hospitalization;
* Under 40 years old;
* Uncontrolled congestive heart failure;
* History of stroke in the past three years;
* Inability to perform study procedures;
* Medical or physical conditions that would preclude participation (e.g., severe arthritis or mobility problems, uncontrolled hypertension or diabetes, renal failure, history of angina with activity);
* On medications that could adversely affect cognition, e.g.: antipsychotics, opioids, stimulants, chemotherapy;
* Psychotic disorders;
* Confounding neurologic conditions (e.g., active central nervous system opportunistic infections, seizure disorders, head injury with loss of consciousness \>30 minutes, intracranial neoplasms, stroke with neurological or neuropsychiatric sequelae);
* Substance Use Disorder, Major Depressive and Generalized Anxiety Disorders within six months of evaluation;
* Hohn \& Yahr \> 3
* MoCA \<17
```

## Locations (1)

- Emory University, 57 Executive Park S NE, Ste 200, Atlanta, Georgia, United States _(33.7490, -84.3880)_
  - Madeleine Hackney, PhD — (CONTACT) — mehackn@emory.edu

## Central Contacts

- Madeleine Hackney, PhD — (CONTACT) — 314-412-4852 — mehackn@emory.edu
- Hannah Kim — (CONTACT) — hannah.kim3@emory.edu

---

*Canonical: https://parkinsonspathways.com/trial/NCT07382674*  
*HTML version: https://parkinsonspathways.com/trial/NCT07382674*  
*Source data: https://clinicaltrials.gov/study/NCT07382674*